Similar risk of exercise‐related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross‐over trial. Issue 2 (27th November 2015)

• Record Type: Journal Article
• Authors: Heise, T.; Bain, S. C.; Bracken, R. M.; Zijlstra, E.; Nosek, L.; Stender‐Petersen, K.; Rabøl, R.; Rowe, E.; Haahr, H. L.
• Is Part Of: Diabetes, obesity & metabolism. Volume 18:Issue 2(2016)
• Page Start: 196
• Page End: 199
• Publication Date: 2015-11-27
• Subjects: exercise -- glycaemic control -- insulin therapy -- type 1 diabetes; Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.12588
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract : We compared changes in blood glucose (BG) and risk of hypoglycaemia during and after exercise in 40 patients with type 1 diabetes (T1D) treated with insulin degludec (IDeg) or insulin glargine (IGlar) in a randomized, open‐label, two‐period, crossover trial. After individual titration and a steady‐state period, patients performed 30 min of moderate‐intensity cycle ergometer exercise (65% peak rate of oxygen uptake). BG, counter‐regulatory hormones and hypoglycaemic episodes were measured frequently during and for 24 h after exercise. BG changes during exercise were similar with IDeg and IGlar [estimated treatment difference (ETD) for maximum BG decrease: 0.14 mmol/l; 95% confidence interval (CI) −0.15, 0.42; p = 0.34], as was mean BG (ETD −0.16 mmol/l; 95% CI −0.36, 0.05; p = 0.13). No hypoglycaemic episodes occurred during exercise. Post‐exercise mean BG, counter‐regulatory hormone response and number of hypoglycaemic episodes in 24 h after starting exercise were similar with IDeg (18 events in 13 patients) and IGlar (23 events in 15 patients). This clinical trial showed that, in patients with T1D treated with a basal‐bolus regimen, the risk of hypoglycaemia induced by moderate‐intensity exercise was low with IDeg and similar to that with IGlar.